SeraCare Life Sciences — Investor Presentation (June 2008)
22 slides from SeraCare Life Sciences's investor presentation, Jun 25, 2008
Slide 1: SeraCare Life Sciences
SeraCare Life Sciences NASDAQ: SRLS June 25, 2008
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this presentation are forward
Slide 3: SeraCare: Products and Services for the Life Sciences Industry
SeraCare: Products and Services for the Life Sciences Industry SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, validation and production of human diagnostics and therapeutics.
Slide 4: Key Events
Key Events March 06 Stock delisted; Bankruptcy filing Summer 06 Sue Vogt & Greg Gould hired May 07 Emerged from bankruptcy New BOD $20M rights offering June 07 $10M line of credit Sold less profitable lines of business; reengineered sales team; focused on product development Sept 2007 $23.7M NIH con
Slide 5: Today and Looking Forward
SeraCare Today and Looking Forward Best-in-class reputation for quality products and services First class customer base Attractive market opportunities In vitro diagnostics Biotechnology and pharmaceutical Evolution of personalized medicine Near-term goal of double-digit revenue growth Strategy for
Slide 6: Customer Universe
SeraCare Customer Universe Drug & Vaccine Research, Development, Manufacturing pissTeenees + human and bovine serum albumin lood Testing ‘* PBMCs, ELISpot, chromogens + controls and panels + serology and NAT + eQuality software suite Research & : Clinical Trials In vitro Diagnostic Research, Develop
Slide 7: Some of Our Valued Customers
Some of Our Valued Customers Pharmaceutical and Biotechnology In Vitro Diagnostics Manufacturers Diagnostics Government Agencies Laboratories, Blood Banks, Proficiency
Slide 8: Global Sales & Distribution
Global Sales & Distribution 14 sales representatives in U.S. Distributors in 6 countries 2 sales representatives (Germany and Spain) Distributors in 19 countries Distributors in 7 countries Distributors in 2 countries Americas Europe Pacific Rim Middle East / Africa
Slide 9: SeraCare Business Segments
PRODUCTS SERVICES SeraCare Business Segments Manufacturing & Research Products Quality Control Products Biobanking & Research Services
Slide 10: Quality Control Products
Quality Control Products ~60% to 70% of all medical decisions involve a diagnostic test Vertically integrated consumer base across growing diagnostics market Diagnostic controls used to verify integrity of test results Reference labs Hospital labs Blood banks IVD manufacturing
Slide 11: Quality Control Products: ACCURUN Controls
SeraCare Quality Control Products ACCURUN(r) Controls Quality control and validation panels Comprehensive selection of infectious disease markers, both serology and nucleic acid testing (NAT) ACCURUN eQuality Integrated Quality Control Software Suite Projected launch Q109
Slide 12: Manufacturing and Research Products
Manufacturing and Research Products Products used in the discovery, development and manufacturing of diagnostics, therapeutics and vaccines Explosive growth in biomarker discovery 50%+ growth in new clinical trials Dramatically increasing funding for vaccine research and development Broad applicatio
Slide 13: Manufacturing and Research Products
SeraCare Manufacturing and Research Products Human processed plasma Cell culture supplements Plasma-derived excipients Seroconversion panels Characterized disease state plasma Cellular immunology products Cultured viruses
Slide 14: Biobanking and Research Services Markets
Biobanking and Research Services Markets Clinical trials and research support services Clinical specimen management Testing services National Cancer Institute initiative to increase quality of biospecimens Increased emphasis on risk management makes biobanks critical partners in product development
Slide 15: Biobanking
SeraCare Biobanking Managing/storing over 18 million biological samples for government and commercial customers Over 80,000 square feet dedicated to repository operations SeraCare has the best-in-class biorepository
Slide 16: Research Services
SeraCare Research Services Clinical trial support, viral culture and molecular services Contract research services in molecular biology, virology and immunology Custom BioServices provide support for many segments of the life science industry
Slide 17: Market Trends Converge: Era of Personalized Medicine
Market Trends Converge: Era of Personalized Medicine Identify new disease-related biomarkers Stratify patient populations for specific therapies Make better, safer medication choices Insure appropriate dosing options Facilitate more focused, faster clinical trials Optimize utilization to decrease ov
Slide 18: The SeraCare/Customer Value Chain: Case Study
The SeraCare/Customer Value Chain: Case Study Discovery Development Manufacturing Clinical Use SRLS provides Performance Panels to aid in test development SRLS develops positive controls to validate test results SRLS becomes approved supplier of reagents used in manufacturing of kit SRLS supplies ex
Slide 19: Management Team
Management Team Susan L.N. Vogt, President & Chief Executive Officer Millipore Corporation Gregory A. Gould, Chief Financial Officer Integrated BioPharma, Atrix Laboratories, Colorado MEDtech Ronald R. Dilling, Vice President, Operations Celliance, Hazelton Biologics (JRH BioSciences) Kathryn E. She
Slide 20: Financials - 2Q08, Ending 3/31/08
Financials - 2Q08, Ending 3/31/08 Revenue $12.5 million vs. $14.0 million Q207 Gross margins $4.7M (38% of revenue) Operating loss $0.2M vs. $3.8M Q207 Net loss $0.3M ($0.02 per share) vs $3.9M ($0.27) Q207 Cash and equivalents $6.0 million Total assets $61.6 million 18.6 million shares outstanding
Slide 21: Corporate Growth Strategy
Corporate Growth Strategy Focus on core segments - molecular diagnostics, vaccine development and cellular assays Increased sales coverage Expanded distribution channels Introduction of new products Controls for genetic testing Cellular products for immune response monitoring Expand business ex-US C
Slide 22: SeraCare Life Sciences
SeraCare Life Sciences NASDAQ: SRLS June 25, 2008
SeraCare Life Sciences — Investor Presentation (June 2008) on 6ix